Is MBIO or MBRX more undervalued in 2026?

CirclFi compares Mustang Bio, Inc. (MBIO) and Moleculin Biotech, Inc. (MBRX) using 13 institutional-grade valuation models. MBIO has a Quality of Company score of 3.5/10 while MBRX scores 4.3/10.

Which is a better buy — MBIO or MBRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MBIO and MBRX valuations compare?

MBIO at $0.63 and MBRX at $2.74 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MBIO vs MBRX Valuation Comparison 2026 — Intrinsic Value Analysis

MBIO

Biotechnology

Mustang Bio, Inc.

Quality

3.5

out of 10

Value Trap

LOW

Price

$0.63

Last close

Models

6/13

Active

MBRX

Biotechnology

Moleculin Biotech, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$2.74

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	MBIO Fair Value	MBIO Upside	MBRX Fair Value	MBRX Upside
Bayesian DCF	Intrinsic	$1.30	+104.8%	$1.77	-35.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.76	+0.7%	$7.87	+187.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MBIO vs MBRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MBIO vs MBRX — Which Stock Is More Undervalued?

MBRX scores higher with a 4.3/10 quality rating vs MBIO's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Mustang Bio, Inc. (MBIO) and Moleculin Biotech, Inc. (MBRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MBIO currently trades at $0.63 with a QOC of 3.5/10, while MBRX trades at $2.74 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).